Source: Annual Congress 2002 - Drug resistance
Disease area: Respiratory infections

Abstract

Objective: to assess if there is association between treatment of patients with pulmonary TB with second-line anti-TB drugs and drug resistance development in sputum secondary microflora
Methods: The culture of sputum of patients with pulmonary TB for nonspecific microflora has been done by quantifiable calculation method with anti-TB drug resistance testing. Blood and chocolate agar media were used.
Results: 73 pulmonary TB patients that got treatment at CTRI in 2001 were included into the study. MDR TB patients on individual treatment regimens (based on DST results) including Ofl, Km, Cap, Aug etc. comprised study group (46 patients). Patients treated on WHO-recommended DOT strategy category I or II were control (C) group (27 patients). Patient's mean age was 34,178+12,073 years. 39.1% of patients in study group had infiltrative TB (55,6 % in C), fibrous-cavernous 26,1% (11,1% in C), disseminated 11,9% (19,2% in C), cavernous -13% (14,8% in C), caseous pneumonia 6,9% (0 in C). Str.-a hemolyticus, Pseudomonas aeruginosa, Candida, Diplococcus crossus, Enterobacter aerugenosa etc prevailed among secondary pathogens. From 1 to 4 different secondary pathogens were cultivated from a single patient.
The frequency of secondary flora resistance in study group to Kanamycin was 65% (25% in C, p<0.05), 60% to Rifampicin (33% in C, p>0.05), 50% to Ofloxacin (0% in C, p<0.005).
Conclusions: there is association between treatment on individual regimens that included FQ and Kanamycin and sputum secondary microflora resistance in pulmonary TB patients. This can be complication of treatment with second-line drugs.

Rating:

Share or cite this content

Citations should be made in the following way:
E. Livchane, L. G. Selina, Y. E. Khromova (Moscow, Russia). Resistance of sputum nonspecific microflora in MDR TB patients treated with second-line anti-TB drugs. Eur Respir J 2002; 20: Suppl. 38, 3838

Member's Comments

No comment yet.

Related content which might interest you: Resistance to second-line antituberculous drugs of Mtb strains in TB institute clinic Source: Eur Respir J 2007; 30: Suppl. 51, 442s Year: 2007 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes Source: Eur Respir J 2013; 42: 156-168 Year: 2013 Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 650s Year: 2005 Efficacy of empiric chemotherapy regimen in patients with multidrug resistant (MDR) tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 656s Year: 2004 Treatment of resistant tuberculosis in patients having isolates resistant to multiple antituberculosis drugs Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010 Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy Source: Eur Respir J 2001; 17: 641-646 Year: 2001 Outcomes for multidrug-resistant tuberculosis patients with and without resistance to fluoroquinolones and second-line injectable drugs: A meta-analysis of individual patient data Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Side-effect in the treatment of pulmonary tuberculosis by first-line drugs Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009 Impact of drug resistance over sputum conversion in tubercular patients receiving re-treatment regimen Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011 The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Second-line anti-tuberculosis drug concentrations for susceptibility testing in the MODS assay Source: Eur Respir J 2013; 41: 1163-1171 Year: 2013 Antituberculosis activity of rifabutin in vitro and in patients with pulmonary drug resistant tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003 A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004 Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003